Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network
23 6월 2021 - 9:01PM
Business Wire
Through this strategic partnership, the network
aims to reach more than 25,000 physicians and 40 million patients,
accelerating trial recruitment and enrollment efforts and expanding
patients’ access to clinical research
Veradigm®, a leading provider of healthcare data and technology
solutions and a business unit of Allscripts Healthcare Solutions
(NASDAQ: MDRX), and PRA Health Sciences, Inc. (NASDAQ: PRAH), one
of the world’s leading global contract research organizations,
announced today the creation of the industry’s leading electronic
healthcare records-based clinical research network that reaches
more than 25,000 physicians and 40 million patients across the
United States.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210623005202/en/
Using Veradigm’s StudySource platform, which extends existing
EHR systems to include clinical research, alongside PRA’s
proprietary eSource technology and clinical research expertise,
this network will enable any of our physicians to offer clinical
research as a care option (CRACCO) to their patients – driving
efficiencies across the trial process and increasing the
accessibility and diversity in clinical trials.
“The current approach to clinical trials is disconnected from
healthcare delivery and requires manual data collection, which
creates barriers for physicians and patients to participate. Today,
less than one percent1 of the US population participates in
clinical research, despite patients’ willingness to participate if
asked2,” said Stephanie Reisinger, Vice President and General
Manager of Veradigm’s Life Sciences Research business. “Under this
agreement, the Veradigm and PRA-led network aims to transform the
clinical research processes by extending EHR workflows to include
clinical research as well as fully leveraging the rich data from
digital healthcare delivery. The scale of Veradigm’s EHR footprint
with PRA’s eSource technology and deep trial expertise will enable
us to literally bring studies to where the patients are.”
In addition to being a burden on patients, clinical trials also
can be a challenging process for trial sites and sponsors. Data
management and monitoring are two of the most lengthy and costly
stages of a clinical trial, yet much of this data already exists in
EHR systems. With PRA’s proprietary eSource technology, data
transfers can be automated from Veradigm’s EHRs to an electronic
data capture system. This approach enables clients to speed drug
development by decreasing the effort and time in this stage and
reducing transcription errors, which provides improved data quality
and reduces the need for costly source data verification.
“Integrating clinical research and clinical care is the model
for achieving the best patient outcomes and for lowering costs for
sponsors, physicians, and patients alike,” Kent Thoelke, Executive
Vice President and Chief Scientific Officer, PRA Health Sciences.
“With this partnership and network, we are leading the industry by
expanding clinical research as a care option (CRACCO) to patients
who have never had an opportunity to participate. We are evolving
and modernizing the drug development paradigm by integrating it
with everyday healthcare delivery.” Technologies supporting both
Veradigm and PRA Health Sciences are securely hosted in the
Microsoft Azure.
Contact us if you would like to learn more about the Veradigm
and PRA and Clinical Research Platform.
1Source: Clinical Research Participation as a Care Option, PMG
Research, 2015
2Source: Research! America, National Poll on Clinical Research,
June 2013
About Veradigm®
Veradigm is an integrated data systems and services company that
combines data-driven clinical insights with actionable tools to
help healthcare stakeholders improve the quality, efficiency, and
value of healthcare delivery— including biopharma, health plans,
healthcare providers, health technology partners, and most
importantly, the patients they serve. We are dedicated to
simplifying the complicated healthcare system with next-generation
healthcare solutions. This is how we are transforming health,
insightfully. To learn more, visit http://www.veradigm.com.
Veradigm® is a business unit of Allscripts.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information
technology solutions that advance clinical, financial and
operational results. Our innovative solutions connect people,
places and data across an Open, Connected Community of Health™.
Connectivity empowers caregivers to make better decisions and
deliver better care for healthier populations. To learn more, visit
www.allscripts.com, Twitter, YouTube and It
Takes A Community: The Allscripts Blog.
About PRA Health Sciences
PRA Health Sciences is one of the world’s leading global
contract research organizations by revenue, providing outsourced
clinical development and data solution services to the
biotechnology and pharmaceutical industries. PRA’s global clinical
development platform includes more than 75 offices across North
America, Europe, Asia, Latin America, Africa, Australia and the
Middle East and more than 19,000 employees worldwide. Since 2000,
PRA has participated in approximately 4,000 clinical trials
worldwide. In addition, PRA has participated in the pivotal or
supportive trials that led to U.S. Food and Drug Administration or
international regulatory approval of more than 95 drugs. To learn
more about PRA, please visit www.prahs.com.
© 2021 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210623005202/en/
Investors: Stephen Shulstein
312-386-6735 Stephen.Shulstein@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com INVESTOR INQUIRIES:
InvestorRelations@prahs.com
MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and
Public Relations hurstlaurie@prahs.com | +1 (919) 786-8435
PRA Health Sciences (NASDAQ:PRAH)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
PRA Health Sciences (NASDAQ:PRAH)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024